Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Clinical research trials and A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies. A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies



A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

For Condition: Peripheral T-Cell Lymphoma,Cutaneous T-Cell Lymphoma,Chronic Lymphocytic Leukemia
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.
Details: Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: - Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy. - No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy. - Life expectancy of at least 12 weeks. - Performance status equal to or less than Zubrod 2. - Signed informed consent. - Patients with measurable disease. - Age at least 16 years. - Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000. - Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal. - Adequate renal function defined as serum creatine less than or equal to 1.5 mg %. - No serious intercurrent illness. - Adequate contraception (if applicable). - NO patients with significant cardiac disease, i.e. NYHA class III or IV. - NO experimental clinical trial within 3 weeks of study entry. - NO patients with active CNS disease. - Full recovery from any prior surgical treatment. -NO active active infections.
Total Enrollment: 100

Location and Contact Information:

M. D. Anderson Cancer Center *Recruiting*
Houston,  Texas,  77030
United States
Recruiting Susan  Pilat 713-745-3296


Additional Information:
Study ID Numbers:  DM94-026; 
Study Start Date: September 1994
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038025

Other Chronic Lymphocytic Leukemia Studies:
1. Phase I Study of BL22, a Recombinant Immunotoxin for Treatment of CD22+ Leukemias and Lymphomas

2. Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

3. Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

4. Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas

5. Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Related Studies:

Other Chronic Lymphocytic Leukemia Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
Modify your Search

  Other Chronic Lymphocytic Leukemia Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103